• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
'Press Releases' Section describes most distant clients with latest product-specific, company-related updates is a key value addition to our members because they can use this platform as the easiest, earlier and the most effective means to get noticed quickly.

Our press release programs work hand in hand with our SEO programs to provide a rock solid positioning in all major search engines so as to contemplate the visibility of your message for Worldwide Pharmaceutical industry.
Aphena Ready for Opioid Crisis

Aphena Ready for Opioid Crisis Response Act

Aphena Pharma Solutions Inc. has announced the expansion of its blister packaging capacity with the purchase of a PharmaWorks TF2 blister packaging line with in-line cartoning capabilities, supplementing its recent vault enlargement to handle emerging requirements for DEA-controlled products.

Read more →
Adaptive Biotechnologies

Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech

Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.

Read more →
Alexion Receives Early FDA Approval for ULTOMIRIS™

Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis).

Read more →
NativeCoat™ ECM Surface Coatings

East River BioSolutions releases NativeCoat™ ECM substrates

East River BioSolutions announced the release of NativeCoat™ ECM – a novel line of 2D in vitro cell culture coatings comprised of native tissue-derived extracellular matrix (ECM) that enables scientists to study cells in their tissue-specific microenvironments, leading to more physiologically relevant testing and thus more accurate and actionable scientific results.

Read more →

We use cookies to ensure you get the best experience on this website Privacy Policy